Pfizer Innovent Oncology Deal | Lucid Diligence Brief
Pfizer Innovent Oncology Deal tests China-originated ADC and multi-specific…
Lucid Diligence Brief: SiranBio and GSK SA030 Licensing Agreement
Lucid Diligence Brief: SiranBio and GSK SA030 Licensing Agreement Professional…
Lucid Diligence Brief: Huahui Health x BeOne Medicines $2 billion collaboration for cancer trispecific HH160
Lucid Diligence Brief: Huahui Health x BeOne Medicines $2 billion collaboration…
Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas
Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas…
Lucid Diligence Brief: Angelini Pharma collaboration with Quiver Bioscience on genetic epilepsies
Lucid Diligence Brief: Angelini Pharma collaboration with Quiver Bioscience on…
Lucid Diligence Brief: Altesa BioSciences $75 million Series B for vapendavir in COPD
Lucid Diligence Brief: Altesa BioSciences $75 million Series B for vapendavir…
Lucid Diligence Brief: Madrigal Ribo siRNA deal for MASH
Lucid Diligence Brief: Madrigal Ribo siRNA deal for MASH Professional audiences…
Lucid Diligence Brief: AstraZeneca and CSPC obesity and T2D collaboration
Lucid Diligence Brief: AstraZeneca and CSPC obesity and T2D collaboration…
Lucid Diligence Brief: Formation Bio licenses miR-124 activator FHND5032 from CTFH
Lucid Diligence Brief: Formation Bio licenses miR-124 activator FHND5032 from…
Lucid Diligence Brief: Novartis and SciNeuro BBB “brain-shuttle” Alzheimer’s deal
Lucid Diligence Brief: Novartis and SciNeuro BBB “brain-shuttle” Alzheimer’s…
Lucid Diligence Brief: AirNexis Therapeutics $200 million Series A for PDE3/4 in COPD
Lucid Diligence Brief: AirNexis Therapeutics $200 million Series A for PDE3/4…
Lucid Diligence Brief: Gilead licenses Assembly Bio’s HSV helicase-primase programs
Lucid Diligence Brief: Gilead licenses Assembly Bio’s HSV helicase-primase…